Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.430 +0.050 (+3.62%)

Official Closing Price Updated: 4:10 PM EDT, Jun 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	503,562
Open	1.410
Bid (Size)	1.400 (100)
Ask (Size)	1.440 (100)
Prev. Close	1.380
Today's Range	1.400 - 1.475
52wk Range	0.8500 - 2.230
Shares Outstanding	15,641,611
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

Today 8:30 EDT

Via ACCESS Newswire

MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Candidate for Bundibugyo Ebola Outbreak

May 26, 2026

Via Investor Brand Network

Performance

YTD	+18.2%	+18.2%
1 Month	-7.7%	-7.7%
3 Month	+45.9%	+45.9%
6 Month	N/A	N/A
1 Year	-5.9%	-5.9%

More News

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

May 26, 2026

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $2 Million Registered Direct Offering

May 19, 2026

Via Investor Brand Network

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

May 18, 2026

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak

May 18, 2026

Via Investor Brand Network

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

May 18, 2026

Via ACCESS Newswire

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Development Across Multiple Viral Disease Targets

May 15, 2026

Via Investor Brand Network

MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Prices $2 Million Registered Direct Offering

May 15, 2026

Via Investor Brand Network

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

May 15, 2026

Via ACCESS Newswire

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II

May 15, 2026

Via ACCESS Newswire

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Candidate Following Andes Hantavirus Incident

May 11, 2026

Via Investor Brand Network

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

May 11, 2026

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Participate in D. Boral Capital Global Conference

May 07, 2026

Via Investor Brand Network

MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Orphan Drug Designation for NV-387

May 04, 2026

Via Investor Brand Network

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

May 04, 2026

Via ACCESS Newswire

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment

April 21, 2026

Via Investor Brand Network

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

April 21, 2026

Via ACCESS Newswire

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files for Rare Pediatric Disease Designation for Measles Drug Candidate

April 07, 2026

Via Investor Brand Network

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

April 07, 2026

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Initiate Phase II MPox Trial in DRC

April 01, 2026

Via Investor Brand Network

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

April 01, 2026

Via ACCESS Newswire

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at NIBA Investment Conference As NV-387 Oral Gummies Drug Supply Completed

March 11, 2026

Via Investor Brand Network

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

March 11, 2026

Via ACCESS Newswire

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox

February 12, 2026

Via Investor Brand Network

Frequently Asked Questions

Is NanoViricides, Inc. Common Stock publicly traded?

Yes, NanoViricides, Inc. Common Stock is publicly traded.

What exchange does NanoViricides, Inc. Common Stock trade on?

NanoViricides, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for NanoViricides, Inc. Common Stock?

The ticker symbol for NanoViricides, Inc. Common Stock is NNVC on the New York Stock Exchange

What is the current price of NanoViricides, Inc. Common Stock?

The current price of NanoViricides, Inc. Common Stock is 1.430

When was NanoViricides, Inc. Common Stock last traded?

The last trade of NanoViricides, Inc. Common Stock was at 06/08/26 04:10 PM ET

What is the market capitalization of NanoViricides, Inc. Common Stock?

The market capitalization of NanoViricides, Inc. Common Stock is 22.37M

How many shares of NanoViricides, Inc. Common Stock are outstanding?

NanoViricides, Inc. Common Stock has 22M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.